Samsung Biologics Lands Record $1.41 Billion CMO Deal

Samsung Biologics has started the year with a bang, signing its largest contract to date. On January 14, the company announced via regulatory filing that it had secured a massive Contract Manufacturing Organization (CMO) deal worth KRW 2.07 trillion(USD 1.41 billion) with a European pharmaceutical company.

This contract is the largest in Samsung Biologics’ history and accounts for roughly 40% of its total orders from last year, which amounted to KRW 5.4 trillion(USD 3.68 billion). The deal, which runs through the end of 2030, has confidentiality clauses regarding the client and product.

The agreement breaks Samsung Biologics’ previous record set just three months ago when it signed a KRW 1.7 trillion(USD 1.16 billion) contract with an Asian pharmaceutical company in October. The company’s annual order value in 2024 grew by 1.5 times compared to the previous year.

Samsung Biologics now counts 17 of the world’s top 20 pharmaceutical companies as clients, a result of its production capacity and quality competitiveness. To meet growing demand for biopharmaceuticals, the company is constructing its 5th plant with an 180,000-liter capacity, set to begin operations in April. Once completed, Samsung Biologics will have a total production capacity of 784,000 liters.

On the quality front, the company boasts a 99% batch success rate and has secured 340 manufacturing approvals from global regulatory agencies, including 41 from the U.S. FDA and 36 from the EMA.

Samsung Biologics has also been proactive in promoting its capabilities, participating in major global pharmaceutical and biotech conferences across the U.S., Europe, and Asia. Currently, it is showcasing its CDMO expertise at the 2025 JP Morgan Healthcare Conference in San Francisco, running from January 13 to 16.